tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Vera Therapeutics price target raised to $65 from $61 at Guggenheim

Guggenheim raised the firm’s price target on Vera Therapeutics (VERA) to $65 from $61 and keeps a Buy rating on the shares after the company reported “overwhelmingly positive” topline results from its pivotal Phase 3 ORIGIN 3 trial in IgA nephropathy. Following the data, the firm is increasing its view of the probability of success for atacicept to 90% from 85%, the analyst noted.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1